ASSAY FOR PREDICTING METHOTREXATE SENSITIVITY IN HUMAN BREAST CANCER

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: N/A
Agency Tracking Number: 7621
Amount: $243,000.00
Phase: Phase II
Program: SBIR
Awards Year: 1987
Solicitation Year: N/A
Solicitation Topic Code: N/A
Solicitation Number: N/A
Small Business Information
Aeron Biotechnology, Inc.
3023 Summit Street, Oakland, CA, 94609
DUNS: N/A
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 Adeline J. Hackett, Ph.d.
 (415) 835-9039
Business Contact
Phone: () -
Research Institution
N/A
Abstract
THE LONG-RANGE GOAL OF THIS PROPOSAL IS TO DEVELOP AN IN VITRO TEST TO IMPROVE SELECTION OF THERAPIES FOR INDIVD- UAL BREAST CANCER PATIENTS BY PREDICTING RESPONSE TO METHO- TREXATE. EXISTING ASSAYS FOR BREAST CANCER CELLS CANNOT DE-TERMINE METHOTREXATE SENSITIVITY BECAUSE OF REQUIREMENTS FORFOR FEEDER LAYERS AND MEDIUM COMPONENTS THAT CAN RESCUE SEN-SITIVE CELLS. THIS PROPOSA WILL,THEREFORE, EVALUATE 2 DIF- FERENT APPROACHES: (1) IMPROVING AN EXISTING CLONOGENIC AS- SAY BY MANIPULATING A SERUM-FREE MEDIUM BASED ON MCDB 170, SO THAT METHOTREXAATE TOXICITY IS ACHIEVED; AND (2) DEVELOP-ING A TOTALLY DIFFERENT ASSAY FOR METHOTREXATE RESISTANCE THAT MEASURES UPTAKE OF FLUORESCEIN-CONJUGATED DRUG USING A FLUORESCENCE-ACTIVATED CELL SORTER (FACS). THE LATTER ASSAY DOES NOT REQUIRE CLONAL GROWTH. PHASE I WILL ESTABLISH THE NECESSARY MEDIUM FORMULATION FOR THE CLONAL ASSAY AND SHOW THAT METHOTREXATE DOSE-RESPONSE CURVES ARE FEASIBLE FOR NORMAL AND TUMOR-DERIVED EPITHELIAL CELLS. ADDITIONALLY, PHASE I WILL CONTINUE THE FACS STUDIES AND EXPAND POTENTIAL SOURCES OF CLINICAL MATERIAL AND CORRELATIONS SO THAT DURING PHASE II, BOTH ASSAYS MAY BE CONTINUED AND EVALUATED FOR EFFICACY AND PRACTICALITY. THE ASSAYS DEVELOPED IN PHASE I WILL PROVIDE A MEANS TO ISOLATE METHOTREXATE-RESISTANT CELLS; THEIR MECHANISMS OF RESISTANCE WILL BE EXAMINED DURING PHASE II. THUS, THESE IN VITRO ASSAYS WILL NOT ONLY BE USEFUL FOR PREDICTING PA- TIENT SENSITIVITY TESTING, BUT SHOULD ALSO PROVIDE A BASIC FOR IMPROVED DRUG DESIGN.

* information listed above is at the time of submission.

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government